This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

CIT Advises Amerita In Sale To PharMerica

CIT Group Inc. (NYSE: CIT), a leading provider of financing and advisory services to small businesses and middle market companies, today announced the sale of Amerita, Inc. (Amerita), a provider of home and specialty infusion services, to PharMerica Corporation (PharMerica), an institutional pharmacy services provider. The deal was led by Wesley Smith, Chris Schaefer and Robyn Friedman from CIT Healthcare. CIT Capital Securities LLC acted as the exclusive financial advisor to Amerita. Terms of the transaction were not disclosed. Amerita was a portfolio company of Ferrer Freeman & Company, LLC (FFC), a private equity firm focused on the healthcare industry.

“Together, with PharMerica, we look forward to continuing to provide quality services and support to home and specialty infusion patients,” said Jim Glynn, founder and CEO of Amerita.

David Freeman, a FFC Founding Partner, added, “CIT drove a sale process that yielded a great outcome for FFC and Amerita’s equity holders. We are especially pleased that Jim and his team have the opportunity to continue leading the next phase of Amerita’s growth with PharMerica’s support.”

Editor’s Note

Follow us on Twitter: @citgroup; LinkedIn: LinkedIn.com/company/cit; YouTube: YouTube.com/citgroupvideo, and Facebook: facebook.com/citgroup. Individuals who are interested in receiving corporate news releases can register at cit.com/newsalerts or subscribe to the RSS feed at cit.com/rss.

About Amerita, Inc.

Amerita, Inc. is a specialty infusion company focused on providing complex pharmaceutical products and clinical services to patients outside of the hospital. This market is expanding through a growing bio-pharmaceutical pipeline of infuseable and injectable medications, an aging population that requires additional healthcare services and the country’s need to find more affordable care alternatives. Amerita is headquartered at 20 Fairbanks, Suite 173, Irvine, CA 92618. More information on Amerita is available at www.ameritaiv.com.

About Ferrer Freeman & Company, LLC

Ferrer Freeman & Company, LLC, is a private equity firm located in Greenwich, CT focused exclusively on growth capital investments in the healthcare industry. Since its founding in 1995, FFC has invested over $900 million in 36 portfolio companies. FFC invests in established companies with significant growth opportunities and entrepreneurial management teams. FFC has a demonstrated track record of leveraging its comprehensive healthcare network and decades of experience to help build market leading organizations. More information on FFC is available at www.ffandco.com.

About PharMerica

PharMerica Corporation is a leading institutional pharmacy services company servicing healthcare facilities in the United States. PharMerica operates institutional pharmacies in 44 states. PharMerica’s customers are institutional healthcare providers, such as nursing centers, assisted living facilities, hospitals and other long-term care providers. The Company also provides pharmacy management services to long-term care hospitals.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,004.77 +22.18 0.13%
S&P 500 1,980.62 +1.71 0.09%
NASDAQ 4,459.9820 +15.0730 0.34%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs